Chicago-based biofabrication startup Dimension Inx has raised $3.175 million to close its series seed financing round led by leading early-stage science venture firm KdT Ventures, oversubscribing its seed round. The company plans to use the funding to accelerate the commercial development and approval by the U.S. Food and Drug Administration of its first 3D printed therapeutic implants that tissue repair and regeneration. Founded in 2017 as a spinout from Northwestern University, Dimension Inx has developed a biofabrication process, with patented materials design and manufacturing platform, that creates 3D printed implants for human tissue repair and regeneration. Dimension Inx has partnered with renowned universities and hospitals, like Emory University, The Children’s Hospital of Philadelphia, Carnegie Mellon University, Nanyang Technological University in Singapore, and much more. With the new seed funding, Dimension Inx will be able to create its first therapeutic implants for facial reconstruction in patients following trauma, as well as those with dental malformations due to congenital defects or aging. When Dimension Inx’s original technology spun out of Ramille Shah’s lab at Northwestern University, the Associate Professor of Materials Sciences and Co-Founder of Dimension Inx was attempting to facilitate the translation and commercialization of the 3D printable material technologies developed at her lab. Securing the latest seed funding brings Dimension Inx one step closer to transform its biofabrication technology into a new class of clinical treatments that could dramatically improve the standard of care and address the shortage of donor tissues and organs, validating years of research.
Read the full article at 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing
